Skip to main content
57th ASAM Annual Conference Main banner
Final Program


Preview Program
Feedback

Collaborative Session

Updates on HCV Elimination in the US
Developed in Collaboration with American Association for the Study of Liver Diseases

Friday, April 24, 2026
3:15 PM - 4:30 PM PT
Location: Regatta, Level 4
Despite significant progress in hepatitis C virus (HCV) treatment, new infections continue to outpace cures, with more than 2.4 million people still living with HCV in the U.S. This 90-minute symposium explores the latest data, evolving guidelines, and innovative strategies driving the nation toward HCV elimination. Join leading experts to examine how advances in diagnostics, simplified treatment, and patient-centered care are shaping the next chapter of HCV eradication in 2026.

Learning Objectives:

Learners will be able to:
  • Review the most up to date epidemiology and diagnostics for hepatitis C virus (HCV) testing
  • Explain simplified HCV treatment and updates to the guidelines
  • Characterize the patient perspective of barriers to treatment in care settings
Disclosure(s):
Ponni Perumalswami, MD: No financial relationships to disclose
Carolyn Wester, MD, MPH: No financial relationships to disclose
Pauli Gray: No financial relationships to disclose
Oluwaseun Falade-Nwulia, MBBS, MPH: Abbvie Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Gilead Sciences: Consultant/Advisory Board (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)